Business
BRAIN Biotech AG signs new Revolving Credit Facility with MP Beteiligungs-GmbH
BRAIN Biotech AG signs new Revolving Credit Facility with MP
About this update from Brain Biotech Ag
EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Capital measures / Significant loan agreement BRAIN Biotech AG signs new Revolving Credit Facility with MP Beteiligungs-GmbH 13-Jul-2026 / 12:59 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group . The issuer is solely responsible for the content of this announcement. NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. BRAIN Biotech AG signs new Revolving Credit Facility with MP Beteiligungs-GmbH Zwingenberg, Germany, July 13, 2026 – BRAIN Biotech AG (ISIN DE0005203947; “ BRAIN ” or “ Company ”) has entered into an agreement with MP Beteiligungs-GmbH (MPBG) for a new revolving credit line of €9.0 million. The term ends on December 31, 2028. Interest on the loan amount drawn will be charged at a variable market-conform interest rate of 6-Month-Forward-Euribor plus 233 basis points per annum. This revolving credit line is intended for general corporate financing purposes and scheduled debt services. Notifying person: Martina Schuster BRAIN Biotech AG – Investor Relations – Darmstädter Str. 34-36 64673 Zwingenberg Deutschland www.brain-biotech.com Investor Relations Office Tel.: +49-(0)-6251-9331-0 Fax: +49-(0)-6251-9331-11 E-Mail: [email protected] IMPORTANT NOTICE This announcement may not be published, distributed or released in the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia), Australia, Canada, Japan or any other jurisdiction in which the publication, distribution or release would be unlawful. This announcement does not constitute an offer of securities of the company for sale or a solicitation of an offer to purchase securities of the company. There will be no public offer of securities of the Company. End of Inside Information 13-Jul-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News Language: English Company: BRAIN Biotech AG Darmstädter Straße 34-36 64673 Zwingenberg Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: [email protected] Internet: www.brain-biotech.com ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX EQS News ID: 2364832 End of Announcement EQS News Service 2364832 13-Jul-2026 CET/CEST